SEATTLE, Sept. 22, 2023 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company” (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, today announced that its Board of Directors (“Board”) has approved a reverse stock split of the Company’s outstanding shares of common…Read More
Neoleukin Therapeutics Inc Neoleukin Therapeutics Announces 1for5 Reverse Stock Split
